Effect of Tirzepatide on Cardiovascular Outcomes.
Huston. Jessica J; Orey. Dontia D; Ashchi. Andrew A; Lachapelle. Andrea Ashchi AA; Genovese. Ariana A; Jackson. Jenna J; Ashchi. Ramsey R; Ashchi. Towfeeq T; Ashchi. Majdi M; Sutton. David D; Deeb. Wasim W; Goldfaden. Rebecca F RF
Key Findings
- Tirzepatide is a dual GLP‑1/GIP receptor agonist used for diabetes and obesity
- GLP‑1 receptor agonists have been shown to cut cardiovascular events in high‑risk patients
- Current evidence suggests tirzepatide is likely cardio‑neutral or possibly cardio‑protective, but data are still emerging
Practical Outcomes
- For biohackers interested in weight loss or metabolic health, tirzepatide appears to be a safe option regarding heart health, but it’s still experimental for non‑clinical use. Typical dosing starts low (e.g., 2.5 mg weekly) and is titrated up to 10‑15 mg. Users should monitor blood pressure, heart rate, and get regular cardiac check‑ups, and always consult a medical professional before starting.
Summary
The review says tirzepatide, a drug that activates both GLP‑1 and GIP receptors, looks promising for people with type‑2 diabetes and obesity because it may lower or at least not increase heart‑related risks, similar to other GLP‑1 drugs that are already known to protect the heart.
Abstract
Patients with type 2 diabetes mellitus and obesity have a higher risk of cardiovascular disease and major adverse cardiovascular events. It is important that medication options for these disease states are either cardioprotective or cardioneutral so that the health of the patient is not worsened. Medications in the glucagon-like peptide-1 receptor agonists class decrease cardiovascular risk in those at high or increased risk of cardiovascular events. This review presents and discusses the current clinical and scientific evidence pertaining to tirzepatide, a glucagon-like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor co-agonist.
Study Information
pubmed
2025
2025-10-01T00:00:00.000Z
10.1007/s40256-025-00767-4
15